Abstract
Background
The purpose of this study was to analyze predictive performance of MCV in midterm ischemic events among SCAD patients undergoing elective PCI.
Material/Methods
We retrospectively included 226 consecutive patients with SCAD who received elective PCI. The patients were grouped based on MCV quartile values. The prognostic significance of MCV was assessed using univariate and multivariate Cox proportional hazard regression analyses.
Results
According to MCV quartile points (87.5 fL, 89.7 fL, and 92.4 fL, respectively), the included patients were divided into 4 groups, with an average follow-up of 34.2 months. There were 28 (48.3%) patients with stent thrombosis in the 1st quartile, 24 (29.1%) in the 2nd quartile, 18 (31.6%) in the 3rd quartile, and 15 (27.8%) in the 4th quartile (log-rank test, P=0.027). Multivariate analysis confirmed that MCV 1st quartile (HRadj=2.047, 95% CI 1.041–4.026; P=0.038), ALT (HRadj=1.013, 95% CI 1.004–1.023; P=0.004) and number of PCI vessels (HRadj=1.198 95% CI 1.013–1.415; P=0.034) were risk factors for ischemic events. The restenosis rate in patients belonging to the MCV 1st quartile was 2 times higher than that in MCV 2nd, 3rd, and 4th quartile groups (P=0.007).
Conclusions
MCV value may be independently correlated with restenosis in SCAD patients undergoing PCI. Low MCV predicts high risk of in-stent restenosis.
MeSH Keywords: Coronary Artery Disease, Erythrocyte Indices, Percutaneous Coronary Intervention, Prognosis
Background
Mean corpuscular volume (MCV), a routine index of whole blood count, refers to the mean volume of red blood cells, and can be detected easily with low cost [1–3]. MCV was first used as a diagnostic biomarker for anemia. Recently, several studies have demonstrated that MCV can predict the mortality and morbidity of some diseases, including coronary artery disease [4–6]. Macrocytosis predicts adverse outcomes for cases receiving percutaneous coronary intervention, or those with acute decompensated heart failure [6].
Coronary artery disease (CAD) is a prevalent disease, greatly threatening human health worldwide. Percutaneous coronary intervention (PCI) is a common revascularization strategy in the management of CAD due to its safety profile, low complication rates, symptom relief, and survival benefits [7–9]. MCV and RDW can influence CAD progression, and could be employed as prognostic biomarkers for CAD patients undergoing PCI [10,11]. However, the correlation of MCV with adverse outcomes in patients with stable CAD (SCAD) was rarely discussed in previously published articles.
In this study, we estimated the predictive significance of MCV in midterm ischemic events among SCAD patients undergoing elective PCI.
Material and Methods
Study population and data collection
The present study was carried out in Zhongshan Hospital Fudan University from January 2008 to December 2017, and assessed 16 099 adults undergoing PCI, of which 9269 were SCAD patients. Among them, 1031 patients underwent elective PCI and 698 participants were recruited in the follow-up investigation.
Medical information of the patients, including demographics, concomitant diseases, drug prescriptions, lesion characteristics, and procedures, was retrospectively extracted by an experienced cardiologist. Preoperative whole blood samples were processed to ascertain results on RBC (red blood cell), hemoglobin, hematocrit, MCV, red cell distribution width (RDW), WBC, Neutrophil%, Lymphocyte%, and platelets using an automated blood counter (Sysmex XN-2000 Hematology System; Sysmex Corp., Kobe, Japan). Sysmex CS-5100 automated coagulation analyzers measured fibrinogen and d-dimer levels. Serum TSH, T3, T4, FT3, FT4, total bilirubin (TBIL), ALT (alanine transaminase), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and lipoprotein (a) were determined using a Roche Cobas 8000 automatic biochemical-immune analyzer (Roche Diagnostics, Mannheim, Germany).
Endpoint
Cardiovascular events among the patients were clinically monitored. Cardiovascular events such as cardiac death and in-stent restenosis were considered as endpoints and were retrospectively reviewed in November 2017. Once in-stent restenosis occurred, the patients would receive individualized treatments after comprehensively considering the severity of symptoms, co-morbidities, vascular bed, length of restenotic lesion, and plaque burden. Main treatment strategies included drug eluting stents, stent-grafts, and balloon angioplasty. In addition, the patients also received antiplatelet drugs, beta-blockers, or statins treatments according to the status of their complicated diseases. Follow-up information was recorded at 30 days, 6 months, 1 year, 2 years, and 4 years through telephone calls and follow-ups at a clinic. Survival time referred to the duration between first PCI and first event or final date.
Statistical analysis
Continuous variables are expressed as average ± standard deviation (SD) or median (interquartile range), and their differences between groups were analyzed using the t test (for 2 groups) or Mann-Whitney U test (for more than 2 groups). Normal data distribution was detected using the Shapiro-Wilk test. Patients were grouped according to their quartile points of MCV values. One-way ANOVA or Kruskal-Wallis H was used for comparisons among subgroups. Differences in categorical variables were estimated using the chi-square test or Fisher exact test. Kaplan-Meier method with log-rank test was used for survival analysis. Cox analysis covered clinically important parameters (age, sex, LVEF, hypertension, diabetes, smoke, number of PCI vessels, number of stents, stent length, medication, laboratory results). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated using multiple analysis to identify independent biomarkers for 2-year cardiac mortality. All calculations were accomplished using SPSS 22.0 (IBM Corp, Chicago, IL). Tests were 2-tailed, and P<0.05 suggested statistical significance for results.
Results
Baseline characteristics stratified by MCV quartiles
Patients with malignant tumors (n=85), undergoing reoperation procedures (n=312), or with advanced valve diseases (n=23) were excluded. Unfortunately, 52 patients were further lost in the investigation. Finally, a total of 226 eligible patients were included in our study.
The included patients were grouped according to their quartiles of MCV values. The first quartile was defined as the middle value between the smallest value and the median of the data set (MCV: 87.5fL). The second quartile referred to the median value of MCV (89.7 fL). The third quartile was the middle value between the median and the highest values of MCV (92.4 fL). The patients were divided into 4 groups based on these 3 quartile points of MCV value. In statistical application, the quartiles of a ranked set of data values formed 4 subsets whose boundaries were the 3 quartile points. Thus, individual item might be described as “on the upper quartile”. The quartile method is helpful in analyzing the trends of a dataset.
Baseline information stratified by the quartile of MCV is demonstrated in Table 1. Age showed significant differences among the 4 groups, and patients with higher MCV were older (P=0.017). Other clinical characteristics, including underlying disease and medication history, did not exhibit obvious differences among groups. Laboratory data were also compared among groups, and the results are summarized in Table 2. RBC appeared to be lower in patients with higher MCV levels (P<0.001). RDW in group I was remarkably higher than in other groups (P=0.002). Patients with high MCV were more likely to have high TBIL (P=0.031). Table 3 shows endovascular treatment procedure and the medication at discharge for patients. The stent lengths ranged from 14 to 110 mm, and the average number of placed stents was 1.7±0.8, 1.7±0.8, 1.8±0.7, and 1.6±0.7 in group 1, 2, 3, and 4, respectively (P=0.678). The number of PCI vessels in group 4 was less than in other groups, but without a significant difference (P>0.05). No obvious differences were observed in drugs used, such as antiplatelet drugs, beta-blockers (β1-selective agents), or statins (including atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) among groups (P>0.05).
Table 1.
Baseline clinical characteristics by quartiles of MCV.
| Group I | Group II | Group III | Group IV | P value | |
|---|---|---|---|---|---|
| 59 | 55 | 57 | 55 | ||
| Age (years) | 62±9 | 61±10 | 62±11 | 67±9 | 0.017 |
| Sex no. (%) | 0.734 | ||||
| Male | 40 (67.8) | 37 (67.3) | 43 (75.4) | 40 (72.7) | |
| Female | 19 (32.2) | 18 (32.7) | 14 (24.6) | 15 (27.3) | |
| LVEF (%) | 62.0±9.6 | 63.3±6.6 | 62.3±8.0 | 62.0±8.2 | 0.812 |
| Hypertension no. (%) | 43 (72.9) | 28 (50.9) | 34 (59.6) | 34 (61.8) | 0.116 |
| Diabetes no. (%) | 11 (39.0) | 12 (29.1) | 10 (17.5) | 10 (18.2) | 0.942 |
| Smoke no. (%) | 22 (37.3) | 27 (49.1) | 19 (33.3) | 20 (36.4) | 0.340 |
| Drug application history | |||||
| Antiplatelet | 9 (15.3) | 15 (27.3) | 10 (17.5) | 11 (20.0) | 0.412 |
| Beta blockers | 4 (6.8) | 7 (12.7) | 7 (12.3) | 5 (9.1) | 0.686 |
| Statins | 4 (6.8) | 8 (14.5) | 6 (10.5) | 5 (9.1) | 0.578 |
LVEF – left ventricular ejection fraction; Beta blockers – referring to the β1-selective agents; Statins – including atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
Table 2.
Laboratory findings by quartiles of MCV.
| Group I | Group II | Group III | Group IV | P value | |
|---|---|---|---|---|---|
| 59 | 55 | 57 | 55 | ||
| RBC (mln/mm3) | 4.7±0.5 | 4.5±0.4 | 4.4±0.5 | 4.2±0.4 | <0.001 |
| HB (mmol/L) | 135.6±19.8 | 137.2±14.4 | 137.4±15.9 | 136.7±14.1 | 0.931 |
| HCT (%) | 39.9±5.7 | 40.0±3.9 | 40.2±4.4 | 40.3±3.9 | 0.971 |
| RDW CV (%) | 13.4±1.2 | 13.0±0.7 | 12.7±0.6 | 13.1±1.0 | 0.002 |
| WBC (tys/mm3) | 7.1±1.8 | 7.6±2.4 | 6.8±1.8 | 6.9±2.3 | 0.278 |
| N (%) | 64.8±9.1 | 60.0±14.9 | 61.2±11.5 | 61.3±9.9 | 0.144 |
| L (%) | 26.0±9.0 | 27.9±10.6 | 28.1±9.0 | 28.4±9.4 | 0.532 |
| PLT | 217.3±63.3 | 221.7±45.1 | 200.8±56.0 | 199.3±59.3 | 0.081 |
| FIB | 307.4±95.0 | 288.4±94.9 | 292.9±83.7 | 293.7±68.8 | 0.683 |
| D Dimer | 0.5±0.7 | 0.3±0.4 | 0.4±0.5 | 0.4±0.5 | 0.716 |
| T3 | 1.5±0.3 | 1.6±0.3 | 1.5±0.3 | 1.5±0.3 | 0.773 |
| T4 | 98.8±23.2 | 100.2±19.1 | 94.2±18.4 | 94.7±19.9 | 0.563 |
| FT3 | 4.2±0.7 | 4.3±0.7 | 4.3±0.7 | 4.3±0.8 | 0.737 |
| FT4 | 18.4±18.1 | 15.8±2.3 | 16.1±2.2 | 15.1±2.6 | 0.286 |
| TSH | 2.9±4.4 | 1.88±1.5 | 2.5±1.7 | 2.8±2.4 | 0.241 |
| TBIL | 8.8±3.6 | 8.5±3.3 | 10.4±4.8 | 10.3±4.3 | 0.031 |
| ALT | 26.2±15.1 | 33.7±22.7 | 27.9±23.9 | 26.3±19.1 | 0.185 |
| TC | 4.2±1.1 | 4.3±1.3 | 3.8±1.0 | 4.2±1.0 | 0.076 |
| LDL | 2.2±0.9 | 2.4±1.0 | 2.0±0.9 | 2.3±0.8 | 0.113 |
| HDL | 1.0±0.4 | 1.0±0.3 | 1.1±0.3 | 1.1±0.4 | 0.293 |
| Lp(a) | 392.6±463.4 | 315.6±351.0 | 350.7±372.6 | 315.0±390.6 | 0.698 |
RBC – red blood cell; HB – hemoglobin; HCT – hematocrit; RDW CV – red blood cell distribution width CV; WBC – white blood cell; N – neutrophil; L – lymphocyte; PLT – platelet; FIB – fibrinogen; T3 – triiodothyronine 3; T4 – triiodothyronine 4; FT3 – free triiodothyronine 3; FT4 – free triiodothyronine 4; TSH – thyroid stimulating hormone; TBIL – total bilirubin; ALT – alanine transaminase; TC – total cholesterol; LDL – low-density lipoprotein; HDL – high density lipoprotein; Lp(a) – lipoprotein(a).
Table 3.
Clinical characteristics by quartiles of MCV.
| Group I | Group II | Group III | Group IV | P value | |
|---|---|---|---|---|---|
| 59 | 55 | 57 | 55 | ||
| No. of PCI vessel | 2.7±1.4 | 2.8±1.5 | 2.6±1.5 | 2.2±1.2 | 0.164 |
| No. of stents | 1.7±0.8 | 1.7±0.8 | 1.8±0.7 | 1.6±0.7 | 0.678 |
| Stent length | 44.6±24.0 | 46.5±21.9 | 47.5±22.1 | 39.9±17.8 | 0.369 |
| Discharge medication no. | |||||
| Antiplatelet | 59 (100) | 55 (100) | 57 (100) | 55 (100) | – |
| Beta blockers | 59 (100) | 55 (100) | 55 (96.5) | 55 (100) | 0.396 |
| Statins | 54 (91.5) | 50 (90.1) | 53 (93.0) | 55 (100) | 0.319 |
PCI – percutaneous coronary intervention; Beta blockers – referring to the β1-selective agents; Statins – including atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
Survival analysis and predictors for outcome
The average duration of follow-up was 34.2 months. During this course, 79 patients presented in-stent restenosis. In Kaplan-Meier analysis, the cumulative restenosis rate at 48 months was 35.0%. The incidence of restenosis showed the highest value in the 1st quartile (48.3%) compared with other groups (log-rank test, P=0.027). However, the incidence exhibited no significant differences among the 2nd quartile, 3rd quartile, and 4th quartile groups (29.1% vs. 31.6% vs. 27.8%, P>0.05) (Figure 1).
Figure 1.
Kaplan-Meier curve for primary vessel patency during follow-up stratified by MCV quartile (n=226). Patients in the 1st quartile had lower survival rate than those of 2nd quartile, 3rd quartile, and 4th quartile (P=0.027, log-rank test), but there was no significant difference in survival among patients of the 2nd quartile, 3rd quartile, and 4th quartile (P>0.05).
Cox regression analyses were performed to identify indicators for ischemic events. Univariate analysis demonstrated that LVEF (left ventricular ejection fraction), MCV quartiles, ALT, HDL, number of PCI vessels, and stent length were significantly associated with ischemic events. Summarized hazard ratios (HRs) for LVEF, MCV 1st quartile vs. 2nd quartile, ALT, HDL, number of PCI vessels, and stents length were 0.972 (95% CI 0.950–0.996; P=0.020), 2.037 (95% CI 1.106–3.753; P=0.022), 1.011 (95% CI 1.002–1.020; P=0.014), 0.333 (95% CI 0.146–0.757; P=0.009), 1.219 (95% CI 1.052–1.413; P=0.009), and 1.012 (95% CI 1.002–1.023; P=0.019), respectively (Table 4). The restenosis rate for MCV 1st quartile was approximately 2 times higher than that for MCV 2nd, 3rd, and 4th quartiles, with a baseline hazard ratio of 2.037. After adjustments for confounding factors, the risk of developing ischemic events was still associated with MCV 1st quartile vs. 2nd quartile (HRadj=2.047, 95% CI 1.041–4.026; P=0.038), ALT (HRadj=1.013, 95% CI 1.004–1.023; P=0.004) and number of PCI vessels (HRadj=1.198 95% CI 1.013–1.415; P=0.034), but was not associated with LVEF, HDL, or stent length (Table 5).
Table 4.
Univariable comparison of factors associated with re-infarction event.
| HR | 95% CI | P value | |
|---|---|---|---|
| Age (years) | 1.000 | 0.978–1.022 | 0.993 |
| Sex No. (%) | 1.470 | 0.869–2.487 | 0.151 |
| LEVF (%) | 0.972 | 0.950–0.996 | 0.020 |
| Hypertension no. (%) | 1.097 | 0.700–1.719 | 0.687 |
| Diabetes no. (%) | 0.755 | 0.468–1.220 | 0.252 |
| Smoke no. (%) | 0.903 | 0.576–1.415 | 0.655 |
| Antiplatelet | 1.391 | 0.768–2.522 | 0.276 |
| Beta blocker | 1.558 | 0.678–3.583 | 0.296 |
| Statin | 0.927 | 0.463–1.855 | 0.829 |
| MCV | 0.036 | ||
| Quartile 1 | Ref. | ||
| Quartile 3 | 1.002 | 0.501–2.004 | 0.995 |
| Quartile 4 | 1.089 | 0.555–2.135 | 0.804 |
| RBC (mln/mm3) | 1.213 | 0.767–1.919 | 0.410 |
| HB (mmol/L) | 0.997 | 0.983–1.011 | 0.636 |
| HCT (%) | 0.998 | 0.949–1.050 | 0.946 |
| RDW CV (%) | 1.136 | 0.909–1.420 | 0.262 |
| WBC (tys/mm3) | 1.024 | 0.923–1.135 | 0.658 |
| N (%) | 1.003 | 0.983–1.023 | 0.789 |
| L (%) | 0.993 | 0.969–1.017 | 0.567 |
| FIB | 1.002 | 1.000–1.004 | 0.082 |
| D Dimer | 1.028 | 0.675–1.566 | 0.897 |
| T3 | 0.483 | 0.163–1.176 | 0.101 |
| T4 | 0.990 | 0.976–1.005 | 0.196 |
| FT3 | 0.854 | 0.621–1.175 | 0.333 |
| FT4 | 1.012 | 0.996–1.029 | 0.136 |
| TSH | 0.990 | 0.913–1.074 | 0.810 |
| TBIL | 0.978 | 0.923–1.035 | 0.442 |
| ALT | 1.011 | 1.002–1.020 | 0.014 |
| TC | 1.081 | 0.888–1.316 | 0.436 |
| LDL | 1.042 | 0.819–1.325 | 0.740 |
| HDL | 0.333 | 0.146–0.757 | 0.009 |
| LP(a) | 1.000 | 0.999–1.000 | 0.315 |
| No. of PCI vessel | 1.219 | 1.052–1.413 | 0.009 |
| No. of stents | 1.188 | 0.867–1.627 | 0.284 |
| Stents length | 1.012 | 1.002–1.023 | 0.019 |
LVEF – left ventricular ejection fraction; MCV – mean corpuscular volume; RBC – red blood cell; HB – Hemoglobin; HCT – hematocrit; RDW CV – red blood cell distribution width CV; WBC – white blood cell; N – Neutrophil; L – lymphocyte; FIB – fibrinogen; T3 – triiodothyronine 3; T4 – triiodothyronine 4; FT3 – free triiodothyronine 3; FT4 – free triiodothyronine 4; TSH – thyroid stimulating hormone; TBIL – total bilirubin; ALT – alanine transaminase; TC – total cholesterol; LDL – low-density lipoprotein; HDL – high density lipoprotein; LP(a) – lipoprotein(a); PCI – percutaneous coronary intervention.
Table 5.
Predictors for re-infarction event by multivariate Cox regression.
| HR | 95% CI | P value | |
|---|---|---|---|
| LVEF (%) | 0.976 | 0.953–1.000 | 0.054 |
| MCV | 0.007 | ||
| Quartile 1 | Ref. | ||
| Quartile 2 | 2.047 | 1.041–4.026 | 0.038 |
| Quartile 3 | 0.706 | 0.321–1.551 | 0.385 |
| Quartile 4 | 0.936 | 0.445–1.967 | 0.861 |
| ALT | 1.013 | 1.004–1.023 | 0.004 |
| HDL | |||
| No. of PCI vessel | 1.198 | 1.013–1.415 | 0.034 |
| Stents length | 1.010 | 0.999–1.022 | 0.079 |
LVEF – left ventricular ejection fraction; MCV – mean corpuscular volume; ALT – alanine transaminase; HDL – high density lipoprotein; PCI – percutaneous coronary intervention.
Discussion
We estimated the influences of MCV on the prognosis of CAD patients undergoing PCI surgery. We found that patients with decreased MCV were more likely to undergo in-stent restenosis among the entire population. Moreover, multivariate analysis demonstrated that MCV was significantly correlated with stent thrombosis after adjusting for confounding factors, such as ALT, HDL, number of PCI vessels, and stent length. The patients in the 1st quartile, who had the lowest MCV values, exhibited high risk of restenosis.
The first generation of bare metal stents (BMS) significantly reduced the morbidity of restenosis (to roughly 16–44%) [12]. The first generation of DES reduced the incidence of restenosis to about 20% within 5 years. Newer DES has reduced this even further, to about 5–7% in 5 years [13–15]. Among our selected patients, the morbidity of restenosis (35%) was similar to that reported in earlier published studies. Kaplan-Meier survival analyses showed MCV could predict the occurrence of restenosis. Patients with lowest MCV values exhibited high risk of restenosis. Furthermore, multivariate regression analyses showed that MCV quartiles independently affect in-stent restenosis. Patients with MCV values lower than 87.5 fL exhibited high risk of in-stent restenosis. Myojo et al. reported that macrocytosis obviously increased mortality, as well as main adverse cardiovascular and cerebrovascular events (MACCE), among patients receiving PCI [6]. Our study population consisted of SCAD cases undergoing PCI, which might have influenced our results. Osadnik et al. reported that higher RDW values yielded higher comorbidity rates and mortality rates [10]. Furthermore, RDW can be used as an indicator for mortality among SCAD patients. Our analysis showed no obvious difference in RDW between restenosis and patency groups. The divergences might be attributed to different study populations, relatively small sample size, and genetic heterogeneity. Further investigations are required to address this issue.
The normal size of RBCs ranges from 82 to 100 fL. Gamaldo et al. observed significant, linear, age-related increases in MCV among white people, even after controlling additional blood indices [16]. The results obtained in our study were in accordance with previously published articles. Age was significantly different among the various MCV quartile groups. Bilirubin is an endogenous inhibitor of atherosclerosis, and total bilirubin level possibly influences the risk of cardiovascular diseases [17,18]. Patients with higher MCV values may also have higher TBIL levels. According to our results, patients with higher MCV value had lower susceptibility to restenosis, and the correlation between MCV and TBIL agrees with these findings.
Cox regression analysis showed LVEF, MCV quartiles, ALT, HDL, number of PCI vessels, and stent length were risk factors for restenosis. After adjustment, MCV, ALT and number of PCI vessels were still correlated with restenosis among SCAD patients undergoing PCI. It is surprising that ALT was an independent risk factor for restenosis, though the underlying mechanism remains unknown. We hypothesized that long-term medication use could cause different degrees of liver injury among SCAD patients. Therefore, ALT became an important index of prognosis among SCAD cases undergoing PCI. Stefanini et al. regarded the number of PCI vessels was a vital procedure factor in evaluating PCI [19], and our results are in line with such a conclusion. Our study revealed that MCV quartile were also an independent risk factor. The patients with MCV values within the 1st quartile had high rate of restenosis. However, those in quartile 2, quartile 3, and quartile 4 subgroups did not show significant differences in restenosis incidence. The rate of microcytosis was only 2.2% (5 patients) in our study population, and most of the patients had normal MCV and RDW values. Among these 5 patients, the prevalence of restenosis was 80%. Although the sample size was too small, we still can capture the trend that lower MCV value predicted high risk of restenosis. Further study will shift the focus on microcytosis patients, aiming to explore the phenomena, because the underlying mechanism is still unknown. Decreased MCV is a biomarker for several diseases, including iron deficiency anemia, thalassemia, and other chronic diseases (e.g., microcytic anemia). Inflammation is a leading cause of microcytosis [20–23], and inflammatory reaction appears in each and every step of atherosclerosis from its inception to terminal manifestation [24,25]. The above reasons might explain the close association of small red blood cell size with high risk of restenosis.
MCV is a routine part of complete blood count (CBC) results and is measured by automated blood cell counters, making its detection is easy and inexpensive, and thus not imposing an excessive medical burden on patients or society.
Conclusions
Risk stratification based on MCV value may be an effective and easy way to prevent and quickly treat restenosis among SCAD patients experiencing PCI, thus reducing the occurrence of MACCE and improving patient survival.
Study limitations
There are several limitations in this study. First of all, it was a medium-sized, single-center, retrospective study. Therefore, larger-scale and multi-center surveys are required to confirm the results from this study and to elucidate the precise mechanisms underlying the correlations between lower MCV and restenosis among SCAD patients undergoing PCI. In addition, because they were not available for most patients, our analysis did not include data on alcohol consumption, history of heart failure, or cytological/chemical data (e.g., serum iron level, total or unsaturated iron binding capacity [TIBC or UIBC], ferritin, transferrin, reticulocyte count, and erythropoietin) that might affect MCV values.
Abbreviations
- PCI
percutaneous coronary intervention
- MCV
mean corpuscular volume
- SCAD
stable coronary artery disease
- LVEF
left ventricular ejection fraction
- RBC
red blood cell
- HB
hemoglobin
- HCT
hematocrit
- RDW CV
red blood cell distribution width CV
- WBC
white blood cell
- N
neutrophil
- L
lymphocyte
- PLT
platelet
- FIB
fibrinogen
- T3
triiodothyronine 3
- T4
triiodothyronine 4
- FT3
free triiodothyronine 3
- FT4
free triiodothyronine 4
- TSH
thyroid stimulating hormone
- TBIL
total bilirubin
- ALT
alanine transaminase
- TC
total cholesterol
- LDL
low-density lipoprotein
- HDL
high-density lipoprotein
- Lp(a)
lipoprotein(a)
Footnotes
Source of support: Wei Guo was supported by the National Natural Science Foundation of China (81572064, 81772263), the Key Developing Disciplines of Shanghai Municipal Commission of Health and Family Planning (2015ZB0201, 201440389), and the Projects from the Shanghai Science and Technology Commission (16411952100). Chunyan Zhang was supported by the Shanghai Municipal Commission of Health and Family Planning (201540052)
Conflicts of interest
None.
References
- 1.Tefferi A. Anemia in adults: A contemporary approach to diagnosis. Mayo Clin Proc. 2003;78:1274–80. doi: 10.4065/78.10.1274. [DOI] [PubMed] [Google Scholar]
- 2.Ford J. Red blood cell morphology. Int J Lab Hematol. 2013;35:351–57. doi: 10.1111/ijlh.12082. [DOI] [PubMed] [Google Scholar]
- 3.Cascio MJ, DeLoughery TG. Anemia: Evaluation and diagnostic tests. Med Clin North Am. 2017;101:263–84. doi: 10.1016/j.mcna.2016.09.003. [DOI] [PubMed] [Google Scholar]
- 4.Ueda T, Kawakami R, Horii M, et al. High mean corpuscular volume is a new indicator of prognosis in acute decompensated heart failure. Circ J. 2013;77:2766–71. doi: 10.1253/circj.cj-13-0718. [DOI] [PubMed] [Google Scholar]
- 5.Zhan YL, Zou B, Kang T, et al. Multiplicative interaction between mean corpuscular volume and red cell distribution width with target organ damage in hypertensive patients. J Clin Lab Anal. 2017;31(5) doi: 10.1002/jcla.22082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Myojo M, Iwata H, Kohro T, et al. Prognostic implication of macrocytosis on adverse outcomes after coronary intervention. Atherosclerosis. 2012;221:148–53. doi: 10.1016/j.atherosclerosis.2011.11.044. [DOI] [PubMed] [Google Scholar]
- 7.Cassar A, Holmes DR, Jr, Rihal CS, Gersh BJ. Chronic coronary artery disease: Diagnosis and management. Mayo Clin Proc. 2009;84:1130–46. doi: 10.4065/mcp.2009.0391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bagnall A, Spyridopoulos I. The evidence base for revascularisation of chronic total occlusions. Curr Cardiol Rev. 2014;10:88–98. doi: 10.2174/1573403X10666140331125659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lettieri C, Zavalloni D, Rossini R, et al. Management and long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol. 2015;116:66–73. doi: 10.1016/j.amjcard.2015.03.039. [DOI] [PubMed] [Google Scholar]
- 10.Osadnik T, Strzelczyk J, Hawranek M, et al. Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease. BMC Cardiovasc Disord. 2013;13:113. doi: 10.1186/1471-2261-13-113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Danese E, Lippi G, Montagnana M. Red blood cell distribution width and cardiovascular diseases. J Thorac Dis. 2015;7:E402–11. doi: 10.3978/j.issn.2072-1439.2015.10.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Alraies MC, Darmoch F, Tummala R, Waksman R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017;9:640–51. doi: 10.4330/wjc.v9.i8.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897–907. doi: 10.1016/j.jacc.2010.07.028. [DOI] [PubMed] [Google Scholar]
- 14.Gu H, Hua K, Li W, et al. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. Int J Cardiol. 2015;201:552–60. doi: 10.1016/j.ijcard.2015.02.097. [DOI] [PubMed] [Google Scholar]
- 15.Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819–28. doi: 10.1161/CIRCULATIONAHA.110.004762. [DOI] [PubMed] [Google Scholar]
- 16.Gamaldo AA, Ferrucci L, Rifkind JM, Zonderman AB. Age-related changes in mean corpuscular volume in adult whites and African Americans. J Am Geriatr Soc. 2011;59:1763–64. doi: 10.1111/j.1532-5415.2011.03583.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Chen SC, Lin CP, Hsu HC, et al. Serum bilirubin improves the risk predictions of cardiovascular and total death in diabetic patients. Clin Chim Acta. 2019;488:1–6. doi: 10.1016/j.cca.2018.10.028. [DOI] [PubMed] [Google Scholar]
- 18.Zhang MM, Gao Y, Zheng YY, et al. Association of fasting serum bilirubin levels with clinical outcomes after percutaneous coronary intervention: A prospective study. Cardiovasc Toxicol. 2017;17:471–77. doi: 10.1007/s12012-017-9405-3. [DOI] [PubMed] [Google Scholar]
- 19.Stefanini GG, Byrne RA, Windecker S, Kastrati A. State of the art: Coronary artery stents – past, present and future. Eurointervention. 2017;13:706–16. doi: 10.4244/EIJ-D-17-00557. [DOI] [PubMed] [Google Scholar]
- 20.Brown RG. Determining the cause of anemia. General approach, with emphasis on microcytic hypochromic anemias. Postgrad Med. 1991;89:161–64. 167–70. doi: 10.1080/00325481.1991.11700925. [DOI] [PubMed] [Google Scholar]
- 21.Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016;38(Suppl 1):32–40. doi: 10.1111/ijlh.12527. [DOI] [PubMed] [Google Scholar]
- 22.Kor CT, Hsieh YP, Chang CC, Chiu PF. The prognostic value of interaction between mean corpuscular volume and red cell distribution width in mortality in chronic kidney disease. Sci Rep. 2018;8:11870. doi: 10.1038/s41598-018-19881-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Solak Y, Yilmaz MI, Saglam M, et al. Mean corpuscular volume is associated with endothelial dysfunction and predicts composite cardiovascular events in patients with chronic kidney disease. Nephrology (Carlton) 2013;18:728–35. doi: 10.1111/nep.12130. [DOI] [PubMed] [Google Scholar]
- 24.Pant S, Deshmukh A, Gurumurthy GS, et al. Inflammation and atherosclerosis – revisited. J Cardiovasc Pharmacol Ther. 2014;19:170–78. doi: 10.1177/1074248413504994. [DOI] [PubMed] [Google Scholar]
- 25.Viola J, Soehnlein O. Atherosclerosis – A matter of unresolved inflammation. Semin Immunol. 2015;27:184–93. doi: 10.1016/j.smim.2015.03.013. [DOI] [PubMed] [Google Scholar]